Welcome to our new website! If this is the first time you are logging in on the new site, you will need to reset your password. Please contact us at raps@raps.org if you need assistance.
Your membership opens the door to free learning resources on demand. Check out the Member Knowledge Center for free webcasts, publications and online courses.
The highly-anticipated fifth edition is here! Get the must-have resource for achieving compliance with medical device regulations.
Hear from leaders around the globe as they share insights about their experiences and lessons learned throughout their certification journey.
The European Medicines Agency (EMA) and the European Network for Health Technology Assessment (EUnetHTA) on Monday detailed their priorities for the next three years in a joint work plan.
Much of the 2017-2020 work plan builds on previous and ongoing efforts to streamline processes between regulators and health technology assessment (HTA) bodies.
"By working together, EMA and EUnetHTA help medicine developers to improve clinical research and become more efficient in generating the evidence each of us needs for good decision-making," said EMA Executive Director Guido Rasi.
EMA says the work plan is complimentary to EUnetHTA's Joint Action 3, which seeks to create a sustainable model for scientific and technical cooperation for HTA, and will support efforts called for in a 2016 European Commission HTA Network reflection paper.
Specifically, the work plan lays out nine priority areas for collaboration between EMA and EUnetHTA:
Some highlights of the work plan include creating a single procedure for providing early joint scientific and HTA advice to drugmakers, optimizing postmarketing evidence generation requirements and implementing a process for exchanging information on regulatory outcomes to facilitate EUnetHTA's relative effectiveness assessments (REAs).
The work plan also seeks to clarify the concepts of "significant benefit" and "added therapeutic value" in the context of orphan drugs to improve understanding between
Additionally, the work plan calls for EMA and EUnetHTA to boost their joint efforts in population- and intervention-specific areas, such as pediatric medicines, combination products, companion diagnostics and advanced therapies by engaging with research networks and notified bodies.
EMA, Work Plan
Tags: EUnetHTA, HTA, Health Technology Assessment, Parallel Advice